液体生物标志物检测临床显著性前列腺癌的诊断准确性:多阈值系统评价与诊断性Meta分析
该系统评价与诊断性Meta分析纳入49项研究,评估多种液体生物标志物在多个阈值下检测临床显著性前列腺癌(csPCa)的诊断准确性。基于约登指数的代表性阈值,4K的诊断比值比最高(8.84),其次为MPS(7.0)和PHI(6.28);多阈值Meta分析显示4K的敏感性最高(0.77),PHI的特异性最高(0.72)。作者认为临床决策需结合液体与影像生物标志物。
要点
- 4K在商业液体生物标志物中检测csPCa的诊断性能最高,诊断比值比为8.84。
- 基于约登指数代表性阈值,4K的敏感性和特异性分别为0.87和0.58。
- 多阈值Meta分析中4K敏感性0.77为最高,PHI特异性0.72为最高。
核心结论
- 在检测csPCa方面,4K在商业液体生物标志物中诊断性能最高。
- 基于本Meta分析计算的最佳阈值,4K检测csPCa的敏感性最高,PHI的特异性最高。
- 临床决策需要液体生物标志物与影像生物标志物的联合策略。
研究设计与样本
- 系统评价与诊断性Meta分析,检索PubMed、Web of Science和Scopus(2023年3月),纳入报告液体生物标志物检测csPCa诊断性能的前瞻性和回顾性研究,共49项研究符合纳入标准。
主要发现
- 基于约登指数的代表性阈值,检测csPCa的汇总敏感性和特异性分别为:PCA3为0.85和0.37,PHI为0.85和0.52,4K为0.87和0.58,SelectMDx为0.82和0.56,ExoDx为0.85和0.54,MPS为0.82和0.59。
- 诊断比值比最高为4K(8.84),其次为MPS(7.0)和PHI(6.28)。
- 多阈值Meta分析中,敏感性为4K 0.77、PHI 0.69、PCA3 0.63;特异性为PHI 0.72、4K 0.70、PCA3 0.69。
关键数值与推荐
- 基于约登指数的代表性阈值:PCA3敏感性0.85、特异性0.37;PHI敏感性0.85、特异性0.52;4K敏感性0.87、特异性0.58;SelectMDx敏感性0.82、特异性0.56;ExoDx敏感性0.85、特异性0.54;MPS敏感性0.82、特异性0.59。
- 诊断比值比:4K为8.84,MPS为7.0,PHI为6.28。
- 多阈值Meta分析:4K敏感性0.77、特异性0.70;PHI敏感性0.69、特异性0.72;PCA3敏感性0.63、特异性0.69。
临床怎么用
- 作者认为临床决策需要液体生物标志物与影像生物标志物的联合策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Many liquid biomarkers have entered clinical practice with the praise to improve the detection of clinically significant prostate cancer (csPCa), helping avoid unnecessary prostate biopsies. OBJECTIVE: We aimed to assess the diagnostic accuracy of multianalyte biomarkers for csPCa detection using multiple thresholds. EVIDENCE ACQUISITION: A comprehensive literature search was done through PubMed, Web of Science, and Scopus in March 2023 for prospective and retrospective studies reporting the diagnostic performance of liquid biomarkers for detecting csPCa. The outcomes of interest were the diagnostic performance of liquid biomarkers for csPCa detection and identification of optimal thresholds for each biomarker. EVIDENCE SYNTHESIS: Overall, 49 studies were eligible for this meta-analysis. Using each representative threshold based on the Youden Index, the pooled sensitivity and specificity for detecting csPCa were 0.85 and 0.37 for prostate cancer gene 3 (PCA3), 0.85 and 0.52 for prostate health index (PHI), 0.87 and 0.58 for four kallikrein (4K), 0.82 and 0.56 for SelectMDx, 0.85 and 0.54 for ExoDx, and 0.82 and 0.59 for mi prostate score (MPS), respectively. The diagnostic odds ratio was highest for 4K (8.84), followed by MPS (7.0) and PHI (6.28). According to the meta-analysis incorporating multiple thresholds, the corresponding sensitivity was 0.77 for 4K, 0.69 for PHI, and 0.63 for PCA3; specificity was 0.72 for PHI, 0.70 for 4K, and 0.69 for PCA3. CONCLUSIONS: Regarding the detection of csPCa, 4K had the highest diagnostic performance among the commercial liquid biomarkers. Based on the optimal thresholds calculated by the present meta-analysis, 4K had the highest sensitivity and PHI had the highest specificity for detecting csPCa. Nevertheless, clinical decision-making requires combination strategies between liquid and imaging biomarkers. PATIENT SUMMARY: Novel biomarkers for prostate cancer detection were useful for more accurate diagnosis of clinically significant prostate cancer to avoid unnecessary biopsies.
引用
- Kawada T, Shim SR, Quhal F, et al. Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds. Eur Urol Oncol. 2023. PMID: 37981495. doi:10.1016/j.euo.2023.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。